Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a significant focus in the field of gerontology, particularly regarding their impact on epigenetic aging and healthspan extension. This review synthesizes various studies that highlight the multifaceted benefits of GLP-1 RAs, particularly in relation to metabolic dysfunction and aging.
Mechanisms of Action
GLP-1 RAs have been shown to reduce major adverse cardiovascular events and all-cause mortality in randomized controlled trials. Notably, the SELECT trial reported a 19% reduction in all-cause mortality (hazard ratio [HR] 0.81) among patients with obesity without diabetes. Similarly, the FLOW trial indicated a 24% reduction in the primary kidney composite endpoint (HR 0.76).
These findings suggest that the benefits of GLP-1 RAs extend beyond glycemic control and weight loss, implicating them in broader metabolic processes. Mechanistic studies have identified pathways involving the hypothalamic GLP-1 receptor, AMPK/SIRT1 signaling, and the production of short-chain fatty acids by the microbiome, all of which may contribute to their geroprotective effects.
Epigenetic Aging and GLP-1 RAs
Recent research has also explored the modulation of validated DNA methylation clocks by GLP-1 RAs. The first randomized evidence in 2025 demonstrated significant deceleration of epigenetic aging markers such as DunedinPACE, PCGrimAge, and PhenoAge after 32 weeks of semaglutide therapy. This suggests that GLP-1 RAs may play a role in slowing down the biological aging process.
Future Directions
While the current evidence supports the potential of GLP-1 RAs as geroprotective agents, the authors emphasize the need for definitive trials. Future studies should include prespecified epigenetic aging endpoints, durability follow-up, body-composition assessments, and analyses stratified by sex. Additionally, diverse population representation is crucial for generalizability. The upcoming results from the EVOKE and EVOKE+ trials in early Alzheimer’s disease will be particularly significant in this context.
What this study does not show
This review does not provide definitive evidence on the long-term effects of GLP-1 RAs on healthspan or epigenetic aging, as further trials are needed.
Evidence scorecard
- Analytic validity: Established
- Clinical validity: Partial
- Clinical utility: Not established
The evidence is based on a review of existing studies and trials.